Contraceptive Drugs And Devices Global Market Report 2025

The contraceptive drugs and devices market size has grown strongly in recent years. It will grow from$25.3 billion in 2024 to $27.24 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to factors such as population growth, heightened awareness of family planning, government initiatives and funding, a growing number of working women, and advancements in contraceptive technologies.

The contraceptive drugs and devices market size is expected to see strong growth in the next few years. It will grow to$36.31 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to factors such as the growing demand for long-acting reversible contraceptives, increasing focus on women's reproductive health, the rising prevalence of sexually transmitted infections, expanded access through e-commerce and telehealth, as well as supportive healthcare policies and insurance coverage. Major trends in the forecast period include the development of smart contraceptive devices with digital tracking, biodegradable implants and patches, innovations in hormone-free contraceptives, AI-driven fertility monitoring apps, and the 3D printing of custom-fit contraceptive devices.

The increasing number of government initiatives focused on reproductive health is expected to drive the growth of the contraceptive drugs and devices market. These initiatives aim to promote reproductive health through awareness campaigns, funding, and access to services. Governments are increasingly recognizing the importance of addressing issues such as maternal health, family planning, and access to essential healthcare services, all of which are crucial for societal well-being and development. Government efforts targeting contraceptive drugs and devices aim to increase access to affordable and effective family planning methods, enabling individuals to make informed choices about their reproductive health. For example, in November 2024, the Australian Government Department of Foreign Affairs and Trade announced an allocation of $56.8 million for a new initiative aimed at promoting sexual and reproductive health and rights in Southeast Asia. As a result, the rise in government initiatives related to reproductive health is boosting the growth of the contraceptive drugs and devices market.

Key players in the contraceptive drugs and devices market are focusing on developing innovative products, such as contraceptive vaginal rings, to enhance convenience and expand long-acting contraceptive options. A contraceptive vaginal ring is a flexible, hormone-releasing device inserted into the vagina to prevent pregnancy by inhibiting ovulation. For example, in October 2023, Xiromed LLC, a U.S.-based pharmaceutical company, introduced EnilloRing, a soft, flexible contraceptive vaginal ring designed to release a combination of etonogestrel (a progestin) and ethinyl estradiol (an estrogen) over three weeks to prevent ovulation. As a bioequivalent generic to NuvaRing, EnilloRing provides women with a discreet, convenient, and cost-effective monthly birth control option that eliminates the need for daily dosing, while maintaining the same safety, efficacy, and tolerability as the branded version.

In March 2024, Insud Pharma SL, a Spain-based pharmaceutical company, acquired Viatris Inc.'s women's healthcare business for an undisclosed amount. This acquisition strengthens Insud Pharma’s presence in emerging markets by acquiring two manufacturing facilities in India, enhancing its ability to supply oral contraceptives to global public health institutions. Viatris Inc., a U.S.-based pharmaceutical and healthcare company, specializes in oral and injectable contraceptives.

Major players in the contraceptive drugs and devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co Inc., Bayer AG, Viatris Inc., Teva Pharmaceuticals Ltd, Lupin Limited, CooperSurgical Inc., Mithra Pharmaceuticals, DKT International, Fuji Latex Co Ltd, Agile Therapeutics Inc., Cupid Limited, Veru Inc., Eskag Pharma Pvt. Ltd., Biosante Pharmaceuticals Inc., HLL Lifecare Limited, Afaxys Inc., The Female Health Company (FC2), Mayer Laboratories Inc., and Daré Bioscience Inc.

North America was the largest region in the contraceptive drugs and devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in contraceptive drugs and devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the contraceptive drugs and devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Contraceptive drugs and devices are medical products designed to prevent pregnancy using various methods. Contraceptive drugs typically contain synthetic hormones that inhibit ovulation, thicken cervical mucus, or alter the uterine lining. On the other hand, contraceptive devices include physical barriers that block sperm from reaching the egg and systems inserted into the uterus to prevent fertilization or implantation.

The primary categories of contraceptive products are contraceptive drugs and contraceptive devices. Contraceptive drugs are medications that work by disrupting the normal processes of ovulation, fertilization, or implantation. The technologies involved range from traditional methods and digital contraceptive apps to wearable devices and long-acting reversible contraceptives (LARCs). These products are distributed through various channels such as hospital pharmacies, retail pharmacies, clinics, online platforms, public channels, and non-governmental organizations, serving a diverse range of end users, including both males and females.

The contraceptive drugs and devices market research report is one of a series of new reports that provides contraceptive drugs and devices market statistics, including contraceptive drugs and devices industry global market size, regional shares, competitors with a contraceptive drugs and devices market share, detailed contraceptive drugs and devices market segments, market trends and opportunities, and any further data you may need to thrive in the contraceptive drugs and devices industry. The contraceptive drugs and devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The contraceptive drugs and devices market consists of sales of hormonal pills, emergency contraceptives, contraceptive implants, intrauterine devices (IUDs), condoms, patches, and vaginal rings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.